{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06031415",
            "orgStudyIdInfo": {
                "id": "GS-US-666-6692"
            },
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of GS-0272 in Participants With Rheumatoid Arthritis",
            "officialTitle": "A Multicenter, Randomized, Placebo-Controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Ascending Doses of GS-0272 in Adult Participants With Rheumatoid Arthritis",
            "acronym": "MARASLE",
            "therapeuticArea": [
                "Orthopedics"
            ],
            "study": "study-of-gs-in-participants-with-rheumatoid-arthritis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-04",
            "studyFirstSubmitQcDate": "2023-09-04",
            "studyFirstPostDateStruct": {
                "date": "2023-09-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gilead Sciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA).\n\nThe primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA."
        },
        "conditionsModule": {
            "conditions": [
                "Rheumatoid Arthritis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 87,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: Rheumatoid Arthritis (RA) Cohorts: GS-0272 or Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Part A will include participants with RA. Part A will have 3 cohorts. Each cohort in Part A will be randomized in a 3:1 ratio to receive either ascending doses of GS-0272 or placebo for 12 weeks.\n\nDosing will begin in Cohort 1. Cohorts 2 and 3 will be initiated upon review of blinded safety data from the preceding cohort.",
                    "interventionNames": [
                        "Drug: GS-0272",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Part B: Active RA Cohort: GS-0272 or Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Part B will include participants with moderate-to-severe RA. Part B will have only 1 cohort (Cohort 4). Participants in Cohort 4 will be randomized in a 2:1 ratio to receive either GS-0272 or placebo for 12 weeks.",
                    "interventionNames": [
                        "Drug: GS-0272",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GS-0272",
                    "description": "Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)",
                    "armGroupLabels": [
                        "Part A: Rheumatoid Arthritis (RA) Cohorts: GS-0272 or Placebo",
                        "Part B: Active RA Cohort: GS-0272 or Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)",
                    "armGroupLabels": [
                        "Part A: Rheumatoid Arthritis (RA) Cohorts: GS-0272 or Placebo",
                        "Part B: Active RA Cohort: GS-0272 or Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants Experiencing Adverse Events (AEs)",
                    "timeFrame": "First dose up to Week 12 plus 70 days"
                },
                {
                    "measure": "Percentage of Participants Experiencing Serious Adverse Events (SAEs)",
                    "timeFrame": "First dose up to Week 12 plus 70 days"
                },
                {
                    "measure": "Percentage of Participants With Laboratory Abnormalities",
                    "timeFrame": "First dose up to Week 12 plus 70 days"
                },
                {
                    "measure": "Pharmacokinetics (PK) of GS-0272: AUCtau",
                    "description": "AUCtau is defined as the area under the concentration versus time curve over the dosing interval.",
                    "timeFrame": "Day 1 predose through Day 197"
                },
                {
                    "measure": "PK of GS-0272: Cmax",
                    "description": "Cmax is defined the maximum observed plasma drug concentration.",
                    "timeFrame": "Day 1 predose through Day 197"
                },
                {
                    "measure": "PK of GS-0272: Tmax",
                    "description": "Tmax is defined as the time to maximum observed concentration.",
                    "timeFrame": "Day 1 predose through Day 197"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Prevalence of Antidrug Antibodies (ADAs) for GS-0272",
                    "description": "Prevalence of ADAs will be measured as the proportion of participants who had at least one positive ADA sample (baseline or post-baseline) among all participants evaluable for ADA prevalence.",
                    "timeFrame": "Baseline (Day 1) through Day 197"
                },
                {
                    "measure": "Incidence of ADAs for GS-0272",
                    "description": "ADA incidence will be measured as the proportion of participants who have treatment-emergent ADA sample (post-baseline) among all participants evaluable for ADA incidence.",
                    "timeFrame": "Baseline (Day 1) through Day 197"
                },
                {
                    "measure": "Part B: Change from Baseline in Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) in Participants with Moderate-to-Severe RA",
                    "description": "Disease Activity Score 28 C-Reactive Protein (DAS28 (CRP)) is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), participant's global assessment of disease activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity.",
                    "timeFrame": "Baseline, Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\nPart A (Rheumatoid Arthritis (RA) Cohorts)-Specific Inclusion Criteria:\n\n* Diagnosis of RA at least 3 months prior to screening fulfilling the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.\n* Ongoing treatment with 1 or 2 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for at least 12 weeks prior to the first dose of study drug, with a stable dose for at least 4 weeks prior to the first dose of study drug, as follows:\n* Individuals must not be on a biologic disease-modifying antirheumatic drugs (bDMARD)/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) at Day 1 or during the study and must discontinue b/tsDMARD use for at least 4 weeks (with the exception of rituximab, which must be discontinued for at least 16 weeks) prior to the first dose of study drug.\n\nPart B (Active RA Cohort)-Specific Inclusion Criteria:\n\n* Participant is seropositive as demonstrated by a positive anti-cyclic citrullinated peptide (anti-CCP) antibody and/or positive rheumatoid factor at screening.\n* Participant has an elevated high-sensitivity C-reactive protein (hsCRP) \u2265 1.2 x upper limit of normal (ULN).\n* Participant has 6 or more swollen and tender joints as assessed on the SJC66/TJC68. Distal interphalangeal joints will not be counted towards the 6 joint eligibility.\n* Participant has had inadequate response or intolerance to at least 1 but not more than 2 bDMARD/tsDMARD therapeutics. A lack of efficacy is defined as documented continued or recurrent disease activity after at least 12 weeks of treatment of RA.\n\nKey Exclusion Criteria:\n\n* Meet any of the protocol-specified infection criteria (hepatitis C, Hepatitis B, HIV, tuberculosis, others).\n* Inadequate response or intolerance to more than 2 bDMARDs/tsDMARDs.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gilead Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-833-445-3230 (GILEAD-0)",
                    "email": "GileadClinicalTrials@gilead.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gilead Study Director",
                    "affiliation": "Gilead Sciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Research of West Florida, Inc.",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Clearwater",
                    "state": "Florida",
                    "zip": "33765",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.96585,
                        "lon": -82.8001
                    }
                },
                {
                    "facility": "Altoona Center for Clinical Research",
                    "status": "RECRUITING",
                    "city": "Duncansville",
                    "state": "Pennsylvania",
                    "zip": "16635",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.42341,
                        "lon": -78.4339
                    }
                },
                {
                    "facility": "ARENSIA Exploratory Medicine LLC",
                    "status": "RECRUITING",
                    "city": "Tbilisi",
                    "zip": "0112",
                    "country": "Georgia",
                    "geoPoint": {
                        "lat": 41.69411,
                        "lon": 44.83368
                    }
                },
                {
                    "facility": "IMSP Republican Clinical Hospital \"Timofei Mosneaga\", ARENSIA E.M.",
                    "status": "RECRUITING",
                    "city": "Chisinau",
                    "zip": "MD-2025",
                    "country": "Moldova, Republic of",
                    "geoPoint": {
                        "lat": 47.00556,
                        "lon": 28.8575
                    }
                },
                {
                    "facility": "Kings College Hospital",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SE5 9RS",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Southampton",
                    "zip": "SO16 6YD",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 50.90395,
                        "lon": -1.40428
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study?nctid=NCT06031415"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001168",
                    "term": "Arthritis"
                },
                {
                    "id": "D000001172",
                    "term": "Arthritis, Rheumatoid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007592",
                    "term": "Joint Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000012216",
                    "term": "Rheumatic Diseases"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4476",
                    "name": "Arthritis",
                    "asFound": "Arthritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4480",
                    "name": "Arthritis, Rheumatoid",
                    "asFound": "Rheumatoid Arthritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10621",
                    "name": "Joint Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15045",
                    "name": "Rheumatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6323",
                    "name": "Collagen Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        }
    },
    "hasResults": false
}